Latest News

Our chairman Alan Wooler chosen as “Alpha-1 Leader in Action” in the latest Alpha-1 Global Newsletter

8th June 2018 Our charity is here to bring awareness of AATD and to support those affected.  We are making a big difference and many people rely on our help.  It is wonderful when other groups help to tell others who we are and what we do. In the lat
Read More

Alpha-1 Awareness UK changes charity name

3rd June 2018 Our charity was originally created to support people affected in the UK with AATD.  It didn’t take long before we started to help those from other countries and today we stretch as far as Australia and New Zealand.  It is for this
Read More

AlphaNet’s CEO Robert Barrett to Retire, New CEO named

May 21, 2018 AlphaNet President and CEO Robert C. Barrett has announced his retirement after 20 years at the helm of the innovative not-for-profit organization. The AlphaNet Board of Directors has named Mark B. Delvaux as his successor effective June
Read More

European Lung Foundation advise on planning a flight

ELF (European Lung Foundation) has produced a poster to help make people with lung conditions aware of the steps they should take when planning a flight. It is available as a printable poster and a slide for digital screens; it’s available in 1
Read More

Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment

24th April 2018 As previously disclosed, in July 2017, Kamada submitted a proposed Phase 3 study protocol for Inhaled AAT for treatment of AATD to the FDA.  In response, in August 2017, the FDA issued a letter to the Company stating the agency’s cont
Read More

Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT

12th March 2018 PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-AAT, which is being developed as treatment for a rare g
Read More